A long-term controlled drug-delivery with anionic beta cyclodextrin complex in layer-by-layer coating for percutaneous implants devices

•Anionic beta cyclodextrin retains drug into the layer-by-layer system•Anionic beta cyclodextrin controls drug release from the layer-by-layer system•The effective drug delivery system is readily tunable to different physiological scenarios•The drug delivery system shows antibacterial effect against...

Full description

Saved in:
Bibliographic Details
Published in:Carbohydrate polymers 2021-04, Vol.257, p.117604-117604, Article 117604
Main Authors: Verza, Beatriz S., van den Beucken, Jeroen J.J.P., Brandt, João V., Jafelicci Junior, Miguel, Barão, Valentim A.R., Piazza, Rodolfo D., Tagit, Oya, Spolidorio, Denise M.P., Vergani, Carlos Eduardo, de Avila, Erica D.
Format: Article
Language:English
Subjects:
Coating
Cyclodextrin
Drug delivery
Layer-By-Layer
Percutaneous device
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•Anionic beta cyclodextrin retains drug into the layer-by-layer system•Anionic beta cyclodextrin controls drug release from the layer-by-layer system•The effective drug delivery system is readily tunable to different physiological scenarios•The drug delivery system shows antibacterial effect against Staphylococcus aureus•An extended effect in bacteria reducing on coating was maintained up to 30 days This study demonstrated a drug-delivery system with anionic beta cyclodextrin (β-CD) complexes to retain tetracycline (TC) and control its release from multilayers of poly(acrylic acid) (PAA) and poly(l-lysine) (PLL) in a ten double layers ([PAA/PLL]10) coating onto titanium. The drug-delivery capacity of the multilayer system was proven by controlled drug release over 15 days and sustained released over 30 days. Qualitative images confirmed TC retention within the layer-by-layer (LbL) over 30 days of incubation. Antibacterial activity of TC/anionic β-CD released from the LbL was established against Staphylococcus aureus species. Remarkably, [PAA/PLL]10/TC/anionic β-CD antibacterial effect was sustained even after 30 days of incubation. The non-cytotoxic effect of the multilayer system revealed normal human gingival fibroblast growth. It is expected that this novel approach and the chemical concept to improve drug incorporation into the multilayer system will open up possibilities to make the drug release system more applicable to implantable percutaneous devices.
ISSN:0144-8617
1879-1344
DOI:10.1016/j.carbpol.2020.117604